Cellectar Biosciences to Announce Third Quarter Earnings Results and Host a Conference Call on Thursday, November 2, 2023

Rhea-AI Summary

Cellectar Biosciences to report Q3 2023 financial results on November 2 and host conference call

Positive

• Cellectar Biosciences will report its financial results for Q3 2023 on November 2. They will also host a conference call to discuss financial results and provide an overview of the Waldenstrom’s macroglobulinemia market and their lead product candidate, iopofosine I 131.

Negative

• None.

FLORHAM PARK, N.J., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of targeted drugs for the treatment of cancer, today announced that the company will report its financial results for the three months ended September 30, 2023 on Thursday, November 2, 2023. Management will also host a conference call with investors to discuss financial results and provide an overview focused on the Waldenstrom’s macroglobulinemia market and its lead product candidate, iopofosine I 131, at 8:30 am Eastern Time. Details for the call are as follows:

Conference call & Webcast Details:
Date:	Thursday, November 2
Time:	8:30 am Eastern Time
Toll Free:	1-888-886-7786
International:	1-416-764-8658
Webcast:	Click HERE
Call me™:	Click HERE

Participants may use the dial-in numbers above and be answered by an operator OR click Call me™ link for instant telephone access to the event. The Call me™ link will be made active 15 minutes prior to the scheduled start time.

About Cellectar Biosciences, Inc.
Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer, independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop the next-generation of cancer cell-targeting treatments, delivering improved efficacy and better safety as a result of fewer off-target effects.

The company’s product pipeline includes lead asset iopofosine I 131, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets.

For more information, please visit www.cellectar.com and www.wmclinicaltrial.com or join the conversation by liking and following us on the company’s social media channels: Twitter, LinkedIn, and Facebook.

Contacts

INVESTORS:
Monique Kosse
LifeSci Advisors
212-915-3820
monique@lifesciadvisors.com

MEDIA:
Claire LaCagnina
Bliss Bio Health
315-765-1462
clacagnina@blissbiohealth.com

 

FAQ

When will Cellectar Biosciences report its Q3 2023 financial results?

Cellectar Biosciences will report its Q3 2023 financial results on November 2.

What will Cellectar Biosciences discuss during the conference call?

During the conference call, Cellectar Biosciences will discuss financial results and provide an overview of the Waldenstrom’s macroglobulinemia market and their lead product candidate, iopofosine I 131.

What is Cellectar Biosciences' ticker symbol?

Cellectar Biosciences' ticker symbol is CLRB.

What is Cellectar Biosciences focused on?

Cellectar Biosciences is focused on the discovery, development, and commercialization of targeted drugs for the treatment of cancer.